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Acute exacerbation is a frequent complication of chronic obstructive pulmonary disease (COPD). Recent
studies suggested a role for bacteria such as Streptococcus pneumoniae in the development of acute exacerbation.
For this study, we investigated the following in COPD patients: (i) the epidemiology of pneumococcal coloni-
zation and infection, (ii) the effect of pneumococcal colonization on the development of exacerbation, and (iii)
the immunological response against S. pneumoniae. We cultured sputa of 269 COPD patients during a stable
state and during exacerbation of COPD and characterized 115 pneumococcal isolates by use of serotyping.
Moreover, we studied serum immunoglobulin G (IgG) antibody titers, antibody avidities, and functional
antibody titers against the seven conjugate vaccine serotypes in these patients. Colonization with only pneu-
mococci (monocultures) increased the risk of exacerbation, with a hazard ratio of 2.93 (95% confidence
interval, 1.41 to 6.07). The most prevalent pneumococcal serotypes found were serotypes 19F, 3, 14, 9L/N/V,
23A/B, and 11. We calculated the theoretical coverage for the 7- and 11-valent pneumococcal vaccines to be 60
and 73%, respectively. All patients had detectable IgG levels against the seven conjugate vaccine serotypes.
These antibody titers were significantly lower than those in vaccinated healthy adults. Finally, on average, a
2.5-fold rise in serotype-specific and functional antibodies in S. pneumoniae-positive sputum cultures was
observed during exacerbation. Our data indicate that pneumococcal colonization in COPD patients is fre-
quently caused by vaccine serotype strains. Moreover, pneumococcal colonization is a risk factor for exacer-
bation of COPD. Finally, our findings demonstrate that COPD patients are able to mount a significant immune
response to pneumococcal infection. COPD patients may therefore benefit from pneumococcal vaccination.
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality in adults. According to the
Global Burden of Disease Study, COPD is the fifth most com-
mon disease and fourth leading cause of death in the world.
Both the prevalence and mortality rate are still expected to
increase in the coming decades (11). The chronic course of this
disease is frequently interrupted by acute exacerbation, which
has a major impact on the morbidity and mortality of COPD
patients (17). Acute exacerbation of COPD is characterized by
an acute sustained worsening of the patient’s condition from a
stable state, beyond normal day-to-day variations, which occurs
one to three times a year and may warrant additional treat-
ment (3, 18). Bacterial infections are thought to contribute to
the pathogenesis and clinical course of COPD (20). Several
recent studies have shown a clear association between the
isolation of bacterial species such as Streptococcus pneumoniae,
Moraxella catarrhalis, and Haemophilus influenzae and acute
exacerbation (18). Patel et al. were the first investigators who
observed a significant relation between lower airway coloniza-
tion in the stable state and exacerbation frequency. However,
their study population was too small to investigate the corre-
lation for individual bacterial species (12). In contrast, Sethi et
al. showed a significant increase in the occurrence of exacer-
bation when S. pneumoniae and M. catarrhalis were isolated
(18).
We hypothesize that the prevention of bacterial growth in
the airways of COPD patients will significantly decrease the
occurrence of exacerbation and thus improve the quality of life
for COPD patients. One of the pathogens that is frequently
involved in colonization and infection of COPD patients is S.
pneumoniae. For this pathogen, a 23-valent polysaccharide vac-
cine and a 7-valent conjugate vaccine are available. The 23-
valent vaccine is protective against pneumococcal invasive dis-
ease in adults and elderly patients, but not in children under
the age of two or immunocompromised patients (14). In addi-
tion, the 23-valent polysaccharide vaccine has not shown a
significant reduction in cases of pneumonia in elderly patients
(7). Moreover, the polysaccharide vaccine induces no immu-
nological memory, which necessitates revaccination (2). In
contrast, the conjugate vaccine is effective in young children
against invasive as well as mucosal diseases and elicits immu-
nological memory, but it covers fewer (7) serotypes. To inves-
tigate the relevance of pneumococcal colonization and infec-
tion in COPD patients, we determined the effect of
pneumococcal colonization on the development of exacerba-
tion. In addition, to assess the theoretical role of pneumococ-
cal vaccination in COPD patients, we determined the serotype
distribution among pneumococcal sputum isolates found dur-
ing colonization and infection. Finally, we investigated the
presence of immunoglobulin G (IgG) antibodies against pneu-
mococcal capsular polysaccharides in COPD patients and the
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development of capsule-specific antibodies as a result of pneu-
mococcal infection during exacerbation.
MATERIALS AND METHODS
Study population. Two hundred sixty-nine patients, aged 40 to 75 years, in the
outpatient department of Medisch Spectrum Twente Hospital, Enschede, The
Netherlands, participating in the COPE study and with a history of COPD, were
recruited from May 1999 through March 2000 (19). The patients had to meet the
following criteria: (i) a clinical diagnosis of stable COPD, as defined by American
Thoracic Society criteria; (ii) no history of asthma; (iii) no exacerbation in the
month prior to enrollment; (iv) current or former smoker; (v) age between 40
and 75 years; (vi) a baseline prebronchodilator forced expiratory volume in 1 s
(FEV1) of 25 to 80% that predicted; (vii) a prebronchodilator ratio of FEV1 to
inspiratory vital capacity value of 60% or less; (viii) reversibility value of FEV1
postinhalation of 80 g of ipratropium bromide via a metered dose inhalator
with Aerochamber of 12% the predicted value or less; (ix) a total lung capacity
that was higher than the predicted total lung capacity minus 1.64  the standard
deviation; (x) no maintenance treatment with oral steroids or antibiotics; (xi) no
medical condition with a low survival rate or serious psychiatric morbidity (e.g.,
cardiac insufficiency or alcoholism); (xii) absence of any other active lung disease
(e.g., sarcoidosis). The use of medication such as nasal corticosteroids, theophyl-
lines, chronic use of acetylcysteine, and all other bronchodilators was allowed
(19).
None of the patients were vaccinated with pneumococcal vaccines before
entering the study. Sputum samples were retrieved at 0, 4, 7, and 10 months,
provided that the disease was stable, and during exacerbation. Serum was col-
lected during acute exacerbation (acute-phase serum) and 2 weeks after exacer-
bation (convalescent-phase serum). The diagnosis of exacerbation was made
based on the following criteria: (i) an objective exacerbation, with a 15%
decrease in lung function (FEV1) and/or a 300-ml decrease in FEV1; (ii) a
subjective exacerbation assessed by means of a symptom checklist and a 2-week
diary; and (iii) a clinical exacerbation, as judged by the patient’s own chest
physician (19).
Sputum cultures. Sputa were collected at scheduled visits to the outpatient
department and in cases of exacerbation. The sputum samples were collected in
sterile vials and transported to the microbiology laboratory within 4 h. Sputum
samples were judged microscopically with a low-magnification lens (100) and
had to contain10 epithelial cells and25 leukocytes per field to be considered
representative bronchial samples. A fixed volume of a 1:100 dilution of sputum
was plated onto blood agar, chocolate agar, MacConkey agar, and Sabouraud
agar. The identification of bacterial growth was performed by standard tech-
niques (10). S. pneumoniae, H. influenzae, M. catarrhalis, Pseudomonas aerugi-
nosa, Staphylococcus aureus, Aspergillus, and Candida species and other gram-
negative rods were considered to be potential pathogens. Other bacterial species
were classified as normal flora.
Bacterial colonization was defined as the presence of bacteria in a culture
retrieved from the lower respiratory tract of a clinically stable COPD patient (5).
A bacterial infection was defined by the presence of one or more potential
pathogens in a COPD patient with a clinical exacerbation. A monoculture was
defined as the growth of a single bacterial species, whereas the presence of
multiple bacterial species was defined as a mixed culture.
Serotyping of pneumococcal isolates. In total, 115 pneumococcal isolates were
cultured and serotyped by the capsular swelling method (Quellung reaction),
using commercially available antisera (Statens Serum Institute, Copenhagen,
Denmark) and microscopic observation.
EIA for measuring anti-pneumococcal polysaccharide IgG concentrations.
Concentrations of IgG antibodies were measured by an enzyme immunoassay
(EIA) method as described previously (9). The results are given in micrograms
per milliliter, calculated from the officially assigned IgG values of the 89-SF
reference serum (15), or were converted into units per milliliter by comparison
with the 89-SF reference serum, which was considered to contain 100 U/ml, in
cases for which no IgG values were available.
EIA for measuring the avidity of anti-pneumococcal polysaccharide antibod-
ies. The relative avidities of IgG antibodies for pneumococcal capsular polysac-
charides were determined by the EIA method as described by Anttila et al. (1),
with some minor modifications. Briefly, microtiter plates (Maxisorp; Nunc, Ros-
kilde, Denmark) were coated overnight with 100 l of coating solution, contain-
ing capsule polysaccharides at a concentration of 10 g/ml (LGC Promochem,
Teddington, United Kingdom), per well. Sera were diluted 1:50 in phosphate-
buffered saline (PBS) containing 5% cell wall polysaccharides (Statens Serum
Institute) and incubated at 4°C overnight. Sera were diluted 1:100 in PBS–0.05%
Tween 20, and threefold serial dilutions were incubated for 2 h at 37°C. After
washing, 0.5 M sodium thiocyanate in PBS was added to dissociate antibody-
antigen complexes. After 15 min of incubation at room temperature, the plates
were washed and antibody binding was detected by the addition of alkaline-
phosphatase-conjugated anti-human IgG (Sigma, St. Louis, Mo.). The color was
developed by the substrate p-nitrophenyl phosphate (Sigma). The absorbance
was measured at 405 nm on an EIA reader (SpectraMAX; Molecular Devices,
Sunnyvale, Calif.). Results were expressed as avidity index (AI) values, assigned
as the percentages of antibodies that remained bound to the antigens after
thiocyanate treatment. The high-avidity antibody concentration was calculated
by multiplying the antibody concentration by the AI value. The reproducibility of
the assay was checked by including a control serum in each plate.
Data analysis. The results were analyzed with the statistical software SPSS 10.
The effect of pneumococcal colonization on the time to the first exacerbation
episode was assessed by using multivariate Cox proportional hazard analyses. We
adjusted for potential confounding variables, including age, sex, smoking status,
number of exacerbation episodes in the preceding year, and FEV1% predicted,
as found previously (P. van der Valk, D. Bogaert, E. Monninkhof, J. van der
Palen, P. Hermans, G. Zielhuis, C. van Herwaarden, and R. Hendriks, submitted
for publication). The initial concentrations of antibodies are depicted as geo-
metric mean concentrations (GMC). Avidities are given as the means of the AI
values and high-avidity antibody concentrations. Statistical comparisons between
antibody levels were performed by analysis of variance and independent sample
t tests. The maximum increase in antibody titer was tested for significance by
using the one-sample t test. Statistical significance was set at P values of 0.05.
RESULTS
Sputum samples from 269 patients were obtained at 0, 4, 7,
and 10 months in cases of stable disease. An additional sputum
sample was collected at each hospital visit for an acute exac-
erbation of COPD. In total, 55% of the patient group devel-
oped at least one exacerbation episode during the follow-up
period. In total, 918 stable state sputa and 241 exacerbation
sputa were collected. Of the stable state sputa, 603 cultures
were negative for potential pathogens, whereas 315 cultures
were positive for at least one microorganism (34%). The ex-
acerbation sputa showed significantly more positive cultures
(49%). Mixed cultures were found in 9 and 5% of the sputum
cultures during stable state and exacerbation, respectively. Mon-
ocultures were found significantly more often during exacer-
bation episodes (41%) than during stable states (26%). The
three predominant bacterial species cultured during a stable
state and exacerbation were H. influenzae (19 and 26%, respec-
tively), S. pneumoniae (13 and 13%, respectively), and M. ca-
tarrhalis (9 and 7%, respectively).
We calculated the effect of the colonization status at the
time of randomization on the time to the next exacerbation
episode for 209 patients from whom sputum was available at
that time. We adjusted for potential confounding variables,
including age, sex, smoking status, number of exacerbations in
the preceding year, and FEV1% predicted. Bacterial coloniza-
tion in general did not increase the risk of a first exacerbation
compared to noncolonized patients, nor did pneumococcal
colonization in general (hazard ratio, 1.31; 95% confidence
interval [CI], 0.743 to 2.305). However, the adjusted hazard
ratio for the development of exacerbations in patients with a
pneumococcal monoculture was 2.93 (95% CI, 1.41 to 6.07).
We investigated all 115 pneumococcal isolates in detail by
means of serotyping. The most prevalent serotypes were sero-
types 19F and 3 (13 and 10%, respectively), followed by sero-
types 14, 9L/N/V, 23A/B, and 11 (9% each) (Table 1). The
theoretical vaccine coverages for the 7-valent and 11-valent
pneumococcal conjugate vaccines and the 23-valent polysac-
charide vaccine were 34, 47, and 70%, respectively. Inclusion
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of the expected cross-reactive serotypes increased the theoret-
ical coverages to 60, 73, and 88%, respectively. A separate
analysis of the potential vaccine coverage of pneumococcal
isolates found during a stable state and exacerbation showed
no significant difference (Table 1).
We investigated the presence of IgG antibodies and the AI
of these antibodies for the serotypes included in the 7-valent
conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) for serum
samples obtained from 92 patients. For this purpose, we in-
cluded all first serum samples obtained during the study pe-
riod. Antibody levels against all seven serotypes were detect-
able in all patients. The GMCs of antibodies against the seven
serotypes for the COPD patients as well as for 10 healthy adult
volunteers before and after vaccination with the 7-valent con-
jugate vaccine are depicted in Table 2. The GMCs ranged from
5.04 g/ml for serotype 4 to 55.76 for serotype 6B, with a large
variability (Fig. 1A). The GMCs for healthy adults ranged from
1.7 (serotype 4) to 21.9 (serotype 6B) g/ml before vaccination
to 13.4 (serotype 9V) to 76.7 (serotype 6B) g/ml after conju-
gate vaccination. The mean AIs as well as the mean high-
avidity antibody concentrations with 95% CIs are also shown in
Fig. 1B and C. The AIs ranged from 55% for serotype 6B to
78% for serotype 18C. The high-avidity antibody titers ranged
from 3.4 g/ml for serotype 4 to 30.7 g/ml for serotype 6B.
Because the studied serum samples were collected ran-
domly, i.e., during both a stable state and exacerbation, we
reanalyzed our data with respect to this variable. No significant
difference in antibody titers against the seven tested serotypes
was observed between samples obtained during exacerbation
and during a stable state (data not shown).
We investigated the development of antibodies in response
to colonization with pneumococci during acute exacerbation.
In total, 15 patients, who were colonized with serotypes 14 (4),
9N (4), 9V (3), 19F (3), and 11 (1), were studied during an
exacerbation. We investigated the antibody levels in serum and
the AIs of the antibodies against the capsular polysaccharides
of the pneumococcal serotypes isolated from the patients.
When available, two or three consecutive serum samples were
analyzed, as initial, acute-phase, and convalescent-phase sam-
ples. Furthermore, we calculated the maximum increase in
antibody titer in the consecutive sera for individual patients
(Table 3). We observed a significant rise in antibodies as well
as in high-avidity antibodies, with an average 2.5-fold increase
(Fig. 1D). The mean avidity, which was 70%, did not change
significantly.
DISCUSSION
We investigated the effect of pneumococcal colonization on
the development of exacerbation in COPD patients. Although
patients colonized with bacteria in general did not show an
increased risk of a first exacerbation episode compared to
patients without bacterial colonization, colonization with S.
pneumoniae, specifically when present as a monoculture, did
increase the risk of a first exacerbation, with a hazard ratio of
2.91. Our data support the findings of Sethi et al., who also
showed a significant increase in exacerbations when S. pneu-
moniae was isolated (18), which underscores the role of S.
pneumoniae in the pathogenesis of exacerbations of COPD.
Surprisingly, the presence of pneumococci in combination with
other pathogens in sputum did not cause an increased risk of a
next exacerbation. This might indicate that monocultures
merely represent an infectious state, whereas mixed cultures
are more representative of a stable state of colonization. This
is supported by our data, which show that during exacerbations
of COPD, monocultures of potential pathogenic microorgan-
TABLE 1. Most prevalent pneumococcal serotypes observed in
COPD patients
Serotype Total no. ofisolates (%)
No. of stable
state isolates (%)
No. of exacerbation
isolates (%)
14 10 (8.7) 5 (5.5) 5 (20.0)
19F 15 (13.0) 12 (13.3) 3 (12.0)
23F 8 (7.0) 7 (7.8) 1 (4.0)
3 12 (10.4) 11 (12.2) 1 (4.0)
6Aa 9 (7.8) 7 (7.7) 2 (8.0)
9 L/Na 10 (8.7) 5 (5.6) 5 (20.0)
11 9 (7.8) 6 (6.7) 3 (12.0)
23A/Ba 10 (8.7) 9 (10.0) 1 (4.0)
7-valent 39 (33.9) 30 (33.3) 9 (36.0)
7-valentb 69 (60.0) 52 (57.7) 17 (68.0)
11-valent 54 (47.0) 44 (48.9) 10 (40.0)
11-valentb 84 (73.0) 66 (73.3) 18 (72.0)
23-valent 80 (69.6) 61 (56.8) 19 (76.0)
23-valentb 101 (78.8) 78 (67.8) 23 (92.0)
Total 115 (100) 90 (100) 25 (100)
a Cross-reactive serotype.
b Including cross-reactive serotypes.
TABLE 2. GMCs (g/ml) of anti-pneumococcal antibodies against the seven conjugate vaccine pneumococcal serotypes
Pneumococcal
serotype
GMC (g/ml [95% CI])
COPD patients Healthy adults Healthy adults afterconjugate vaccination
4 5.04 (3.93–6.15) 1.65a (0.48–2.81) 19.95b (5.99–33.92)
6B 55.76 (40.83–70.70) 21.9 (7.02–36.84) 76.70 (46.87–106.53)
9V 16.38 (12.22–20.54) 3.39a (0.85–5.95) 13.41 (8.51–18.31)
14 7.06 (5.11–9.01) 3.37 (0.28–6.47) 30.74b (14.22–47.26)
18C 17.49 (12.59–22.40) 9.37 (3.80–22.54) 56.53b (27.23–85.83)
19F 36.34 (26.29–46.40) 18.40 (4.97–31.82) 66.76 (34.61–98.90)
23F 18.08 (13.13–23.04) 4.08 (0.64–7.50) 55.43b (17.65–93.21)
a Significantly lower antibody level compared to patient group.
b Significantly higher antibody level compared to patient group.
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isms, in particular, are increased. Because this specific corre-
lation has never been investigated, it will be worthwhile to
include this variable in future analyses.
Subsequently, we calculated the theoretical coverage of the
7-valent, 11-valent, and 23-valent pneumococcal vaccines. The
most prevalent serogroups among the 115 isolates investigated
were serogroups 3, 9, 11, 14, 19, and 23 (10, 9, 8, 9, 14, and
16%, respectively). Because most of these serogroups are in-
cluded in the conjugate vaccine, the theoretical coverage for
these vaccines is 34 to 49% of all pneumococci, but is even
higher (60 to 73%) when cross-reactive serotypes are consid-
ered. An analysis of just exacerbation cultures showed compa-
rable coverage rates. This is in agreement with the data of
Flamaing et al., who investigated the serotype distribution
among pneumococcal isolates obtained from individuals 65
years of age and older with invasive disease in Belgium (6). The
potential coverage of the 23-valent conjugate vaccine is even
higher, with 70 to 88% coverage. Unfortunately, most previous
studies could not find a protective effect of this vaccine against
mucosal diseases.
Secondly, we investigated whether natural antibodies were
already present in COPD patients but failed to protect these
patients from pneumococcal colonization. GMCs for the 92
COPD patients investigated were normal to high when com-
pared to healthy adults (M. Sluijter, unpublished observa-
tions). Moreover, as in healthy adults, GMCs for serotypes 4
and 14 were relatively low compared to the other serotypes.
Finally, the quality of the antibodies, as measured by means of
AIs, was sufficient. Therefore, we conclude that these patients
are able to elicit an immunological response to pneumococcal
challenge and thus are not immunologically deficient with re-
spect to antibody development. The trend towards higher titers
FIG. 1. Capsular antibody titers against the seven pneumococcal conjugate vaccine serotypes in 92 COPD patients at the start of the study.
Error bars show 95% CIs for the GMCs for IgG antibodies (A), AIs (B), and high-avidity antibody titers (C). (D) Error bars show 95% CIs for
mean maximum antibody increases and mean maximum high-avidity antibody increases for the homologous serotype during exacerbation.
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compared to healthy unvaccinated adults may represent the
increased pneumococcal contacts in this patient group, al-
though a difference in gender (50 and 98% male, respectively)
and smoking history (0 and 100%, respectively) between the
healthy adults and the patient group may also be of influence
(16).
Healthy adults vaccinated once with the 7-valent conjugate
vaccine displayed higher GMCs than the patient group, al-
though they were only significant for serotypes 4, 14, 18C, and
23F due to the relatively large CIs. Because a similar response
from our patient group can be expected upon vaccination, we
suggest that vaccination of our patient group may increase
antibody levels and hence may elicit a higher level of protec-
tion against pneumococcal disease. This is in agreement with
the results of Jonsson et al., who have shown that vaccination
of COPD patients with a serotype 6B conjugate vaccine or a
23-valent polysaccharide vaccine elicits antibody levels compa-
rable to those in vaccinated healthy adults (8). One might
question, however, whether the present levels of antibodies
prevent both colonization and infection with pneumococci in
our patients. It has been hypothesized that the prevention of
mucosal disease requires higher levels of anti-pneumococcal
antibodies than the prevention of invasive disease. Previous
work has shown that higher antibody levels are necessary to
protect children against acute otitis media than against invasive
diseases (13). Alternatively, one might suggest that anatomical
damage to the lungs and the thick mucous layers prevents the
immune system from recognizing or attacking colonizing bac-
teria. This is supported by the data of Davis et al., who have
shown that vaccination of COPD patients with a 14-valent
pneumococcal polysaccharide vaccine induces significant anti-
body responses but not protection against pneumonia and
death (4). In contrast to our findings, most pneumococci ob-
served during infection in that study were nonvaccine sero-
types, which may explain the observed vaccine failure. We
determined whether the presence of pneumococci during ex-
acerbation elicits a natural immune response to the homolo-
gous serotype. Overall, a 2.5-fold increase in IgG antibody
levels and high-avidity antibody levels was found. Although a
small patient group was studied and a small number of con-
secutive sera per patient were available, these data suggest that
the immune systems of two-thirds of the COPD patients were
capable of mounting an antibody response towards pneumo-
cocci, whereas one-third of the patients did not show an in-
crease in antibodies upon the presence of pneumococci. Ob-
viously, one could argue whether these antibodies protect
COPD patients against pneumococcal reinfection. Follow-up
studies are necessary in which the protective potentials of these
antibodies are investigated in order to speculate about the
effect of pneumococcal conjugate vaccination in COPD pa-
tients.
In conclusion, our data indicate that pneumococcal coloni-
zation in COPD patients is frequently caused by vaccine sero-
type strains. Moreover, pneumococcal colonization is a risk
factor for exacerbations in these patients. Finally, our findings
show that the majority of COPD patients mount an anticap-
sular immune response during pneumococcal colonization and
infection. Clinical studies are needed to investigate the protec-
tive potentials of conjugate vaccination for COPD patients.
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